BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 20, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
March 29, 2021
View Archived Issues
PepGen develops enhanced delivery oligonucleotides for muscular dystrophy
Read More
Albireo initiates dosing in key clinical studies with two of its candidates
Read More
Phase I study of intranasal adenovirus vector COVID-19 vaccine candidate, BBV-154
Read More
Cholesterol-independent heart disease risk gene
Read More
Ultrarare variants give insights into schizophrenia
Read More
T-cell 'auto-aggression' causes liver damage in NASH
Read More
Engineered myeloid cells prevent pro-metastatic microenvironments
Read More
Israeli startup goes bio(me)-prospecting in wild animals
Read More
University of Oxford to launch a phase I study evaluating nasally administered ChAdOx1 nCoV-19
Read More
Intensity Therapeutics to conduct phase II study of INT230-6 in early-stage breast cancer
Read More
AHR as novel therapeutic target for polycystic ovary syndrome
Read More
CC-90011 plus EP/EC shows safety in first-line extensive-stage SCLC
Read More
LINC00926 identified as a prognostic marker in lung adenocarcinoma
Read More
Foresee begins phase II/III study of FP-025 in COVID-19-associated ARDS
Read More
Phase II/III study of arimoclomol in inclusion body myositis misses endpoints
Read More
Researchers develop a Cyp17-overexpressing murine model of PCOS
Read More
Universtiy of Zurich, ETHZ patent bispecific binding agents targeting CD117 and CD3
Read More
HMPL-306 enters international phase I studies in solid tumors and hematological malignancies
Read More
Jiangsu Chia Tai Tianqing Pharmaceutical Group and collaborators describe GTPase KRAS inhibitors
Read More
Shanghai Institute of Materia Medica identifies new AXL and/or MET inhibitors
Read More
New ATX inhibitors identified by Humanwell Healthcare, collaborators
Read More
Phase IIb/III study of Zyesami for respiratory failure in critical COVID-19 meets primary endpoint
Read More
Wigen Biomedicine Technology discovers Wee1hu inhibitors
Read More
FDA approves Abecma for relapsed or refractory multiple myeloma
Read More
Phase Ib interim data on CDX-0159 for antihistamine-refractory chronic inducible urticaria
Read More